From the hope to the ontarget and the transcend studies: challenges in improving prognosis
- 1 January 2002
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 89 (2) , 18-25
- https://doi.org/10.1016/s0002-9149(01)02323-2
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Tissue Angiotensin and Pathobiology of Vascular DiseaseHypertension, 2001
- Effects of Ramipril and Vitamin E on AtherosclerosisCirculation, 2001
- Inhibiting Renin-Angiotensin in the Brain: the Possible Therapeutic ImplicationsBlood Pressure, 2001
- Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart FailureCirculation, 1999
- Increased Accumulation of Tissue ACE in Human Atherosclerotic Coronary Artery DiseaseCirculation, 1996